Are you experiencing chronic cancer pain even on your current opiate medications

What is the SPRAY III study?

SPRAY III (Sativex® for Pain Research in Advanced malignancY) is a clinical research study to determine if the investigational medication Sativex® (nabiximols) is effective in managing chronic cancer pain. An investigational medication is one that has not been approved yet by your country. Sativex® has been approved in Canada as an add-on treatment for pain in patients with advanced cancer.

Sativex® comes in the form of a mouth spray taken by spraying it in your mouth on the inside of your cheeks. More details on how to take this study medication will be provided to you if you decide to participate in the SPRAY III study.

The SPRAY III study is being conducted in many countries, and it is estimated that more than 1,000 patients will be enrolled world-wide.

For more information about the SPRAY III study, please see patient fact sheet below.

SPRAY III Clinical Research Study Patient Fact Sheet


Below is a list of sites participating in the SPRAY III study in your country. Please contact a site of your preference to see if you may be eligible for this study.

    • Bury Lancashire, BL9 7TD
      0161 778 2636

    • Bury St Edmunds, IP33 2QZ
      01284 713580

    • Crumpsall Manchester, M8 5RB
      0161 720 2972

    • Dumfries, DG1 4AP
      01387 241870

    • Edinburgh, EH4 2XR
      0131 777 3518

    • Glasgow, G12 0YN
      0141 2110142

    • Norwich, NR4 7UY
      01603 286162

    • Nottingham, NG5 1PB
      0115 962 7778

    • Weston super Mare, BS23 4TQ
      01934 881135

    • Wolverhampton, WV10 0QP
      01902 695212